rdifazio

5 ms·

1. 1.▲
   by rdifazio 5y ago

   Thanks for the feedback! I'm happy to share more. - They're derived from secondary lymphoid tissue. We're trying to biobank as broadly as we can to capture sex, age, race, HLA, genetics, and other characteristics in a wide ne
2. 2.▲
   by rdifazio 5y ago

   Thanks for the heads up. We're looking into it, but in the meantime robert at parallel.bio or founders at are both good email addresses.
3. 3.▲
   by rdifazio 5y ago

   Please do, and I appreciate the introductions! My email is robert at parallel.bio.
4. 4.▲
   by rdifazio 5y ago

   Thank you! If you have a good recommendation, we'd love an introduction. Please let me know at robert at parallel.bio.
5. 5.▲
   by rdifazio 5y ago

   There are some reviews on immune organoids that I posted below. This is the first human one though able to recapitulate these features at a commercial scale. We haven't gotten any feedback from med chemists yet! The cost is comparabl
6. 6.▲
   by rdifazio 5y ago

   There's been a lot of research around organoids but our human platform is unique. Here are two reviews discussing organoids that have been so far for the immune system, though these have almost all been done in mice ( https:/&#x2F
7. 7.▲
   by rdifazio 5y ago

   We agree that this would be an important step. That being said, there is a paucity of models that would make suitable replacements to animal models. People are working on this issue, but many more people need to be working on developing bet
8. 8.▲
   by rdifazio 5y ago

   We feel exactly the same way. Not only is it unacceptable that over 110 million animals a year are sacrificed for research, but these models do a terrible job of translating to humans and in most cases cannot even model the disease of inter
9. 9.▲
   by rdifazio 5y ago

   We're in the process of launching and are working on coming out of stealth as fast as we can. It shouldn't be empty in the near future!
10. 10.▲
    by rdifazio 5y ago

    Hey everyone! We’re Juliana and Robert, co-founders of Parallel Bio. We're improving drug discovery by replacing animal models, in the hope of making cures for humans, not mice. The biggest reason why 92% of new drugs fail is that drug